An important issue in toxicology is the suitability of the data obtained with experimental animals for human risk assessment. Because it is not possible to use humans in long-term toxicological studies, the use of animals will continue. However, the data obtained in animal studies can be better extrapolated to the patient by utilizing bridging studies with in vitro models of human drug metabolism. There are 2 basic categories of in vitro methods for the examination of human liver drug metabolism. The first group of in vitro methods consists of the cellular models, which include primary hepatocytes, liver slices, and cell lines. The second group is the use of preparations of the drug-metabolizing enzymes such as tissue homogenates, subcellular fractions, and isolated enzymes. Studies modeling both the human and experimental animal metabolism of a drug are useful in the design of toxicological studies. In vitro studies can identify metabolites, species-specific metabolic routes, and the experimental animal model that best reflects the potential human exposure to the drug and its metabolites. This information can also be useful in the design of the clinical studies by identifying human metabolites, the enzymes responsible for the metabolic clearance of the drug, the effects of genetics and other host factors on the metabolism of the drug, and potential drug-drug interactions. An example of how such information is generated and interpreted is presented.
Bonate PL (1991). Gender-related differences in xenobiotic metabolism . J. Clin. Pharmacol. 31: 684-690.
2.
Brendel K., Fisher RL, Krumdieck CL, and Gandolfi AJ (1990). Precision-cut rat liver slices in dynamic organ culture for structure-toxicity studies. J. Am. College Toxicol . 9: 621-627.
3.
Burchell B., Nebert DW, Nelson DR, Bock KW, Takashi I., Jansen PLM, Lancet D., Mulder GJ, Chowdhury JR, Siest G., Tephly TR, and Mackenzie PI (1991). The UDP-glucuronosyltransferase gene superfamily. Suggested nomenclature based on evolutionary divergence. DNA Cell Biol. 10: 487-494.
4.
Caldwell J. (1992). Problems and opportunities in toxicity testing arising from species differences in xenobiotic metabolism. Toxicol. Lett. 64/65: 651-659.
5.
Cholerton S. , Daly AK, and Idle JR (1992). The role of individual human cytochromes P450 in drug metabolism and clinical response . TIPS13: 434-439.
6.
Coundouris JA , Grant MH, Engeset J., Petrie JC, and Hawksworth GM (1993). Cryopreservation of human adult hepatocytes for use in drug metabolism and toxicity studies. Xenobiotica23(12): 1399-1409.
7.
Diaz D., Fabre I., Daujat M., Saint Aubert B., Bories P., Michel H., and Maurel P. (1990). Omeprazole is an aryl hydrocarbon-like inducer in human hepatic cytochrome P450. Gastroenterology99: 737-747.
8.
Falany JL, Lawing L., and Falany CN (1993). Identification and characterization of cytosolic sulfotransferase activities in MCF-7 human breast carcinoma cells. J. Steroid Biochem. Molec. Biol. 46(4): 481-487.
9.
Ferro M., Bassi AM, Penco S., and Nanni G. (1993). Use of established hepatoma cell lines in biotoxicology . Cytotechnology11: S126-129.
10.
Franz PM, Mattiuz EL, Hatcher BL, DeSante KA, Breau AP, Occolowitz JL, Dorman DE, Schmid CR, Goldberg MJ, and Rubin A. (1993). Disposition of zatosetron, a serotonin (5-HT3) receptor antagonist, in humans. Drug Metab. Disp. 21(2): 249-254.
11.
Goldstein JA , Faletto MB, Romkes-Sparks M., Sullivan T., Kitareewan S., Raucy JL, Lasker JM, and Ghanayem BI (1994). Evidence that CYP2C19 is the major (S)-mephenytoin 4'-hydroxylase in humans . Biochemistry33: 1743-1752.
12.
Gonzalez FJ (1992). Human cytochromes P450: Problems and prospects. TIPS13: 346-352.
13.
Gonzalez FJ and Idle JR (1994). Pharmacogenetic phenotyping and genotyping. Present status and future potential. Clin. Pharmacokinet. 26(1): 59-70.
14.
Guengerich FP (1993). Cytochrome P450 enzymes. They defend the body against environmental pollutants, detoxify drugs and synthesize several important signaling molecules. Am. Sci . 81: 440-447.
15.
Guengerich FP, Gillam EMJ, Ohmori S., Sandhu P., Brian WR, Sari MA, and Iwasaki M. (1993). Expression of human cytochrome P450 enzymes in yeast and bacteria and relevance to studies on catalytic specificity . Toxicology82: 21-37.
16.
Guillouzo A. , Morel F., Fardel O., and Meunier B. (1993). Use of human hepatocyte cultures for drug metabolism studies. Toxicology82: 209-219.
17.
Hines RN, Cashman JR, Philpot RM, Williams DE, and Ziegler DM (1994). Contemporary issues in toxicology. The mammalian flavin-containing monooxygenases: Molecular characterization and regulation of expression. Toxicol. App. Pharmacol. 125: 1-6.
18.
Humphrey MJ and Smith DA (1992). Role of metabolism and pharmacokinetic studies in the discovery of new drugs-Present and future perspectives . Xenobiotica22(7): 743-755.
19.
Ingelman-Sundberg M., Johansson I., Yin H., Terelius Y., Eliasson E., Clot P., and Albano E. (1993). Ethanol-inducible cytochrome P4502E1: Genetic polymorphism, regulation, and possible role in the etiology of alcohol-induced liver disease. Alcohol10: 447-452.
20.
Langenbach R., Smith PB, and Crespi C. (1992). Recombinant DNA approaches for the development of metabolic systems used in in vitro toxicology. Mutat. Res. 277:251-275.
21.
Lennard MS (1993). Genetically determined adverse drug reactions involving metabolism. Drug Safety9(1): 60-77.
22.
Mannervik B, Awasthi YC, Board PG, Hayes JD, Di Ilio C, Ketterer B, Listowsky I, Morgenstern R, Muramatsu M, Pearson WR, Pickett CB, Sato K, Widersten M, and Walf CR (1992). Nomenclature for human glutathione transferases. Biochem. J. 282: 305-306.
23.
McLean AJ and Morgan DJ (1991). Clinical pharmacokinetics in patients with liver disease. Clin. Pharmacokinet. 21(1): 42-69.
24.
Mimura M., Baba T., Yamazaki H., Ohmori S., Inui Y., Gonzalez FJ, Guengerich FP, and Shimada T. (1993). Characterization of cytochrome P-450 2B6 in human liver microsomes. Drug Metab. Disp. 21(6): 1048-1056.
25.
Nelson DR, Kamataki T., Waxman DJ, Guengerich FP, Estabrook RW, Feyereisen R., Gonzalez FJ, Coon MJ, Gunsalus IC, Gotoh O., Okuda J., and Nebert DW (1993). The P450 superfamily: Update on new sequences, gene mapping, accession numbers, early trivial names of enzymes, and nomenclature . DNA Cell Biol. 12(1): 1-51.
26.
Peck CCTemple R., and Collins JM (1993). Understanding consequences of concurrent therapies . JAMA269(12): 1550-1552.
27.
Ring BJ, Parli CJ, George MC, and Wrighton SA (1994). In vitro metabolism of zatosetron. Interspecies comparison and role of CYP 3A. Drug Metab. Disp. 22(3): 352-357.
28.
Romkes M., Faletto MB, Blaisdell JA, Raucy JL, and Goldstein, JA (1991). Cloning and expression of complementary DNAs for multiple members of the human cytochrome P450IIC subfamily. Biochemistry30: 3247-3255.
29.
Shimada T., Yun CH, Yamazaki H., Gautier JC, Beaune PH, and Guengerich FP (1992). Characterization of human lung microsomal cytochrome P-450 1A1 and its role in the oxidation of chemical carcinogens. Mol. Pharmacol. 41: 856-864.
30.
Watkins PB, Murray SA, Winkelman LG, Heuman DM, Wrighton SA, and Guzelian PS (1989). Erythromycin breath test as an assay of glucocorticoid-inducible liver cytochromes P-450. Studies in rats and patients. J. Clin. Invest. 83: 688-697.
31.
Wrighton SA and Stevens JC (1992). The human hepatic cytochromes P450 involved in drug metabolism. Crit. Rev. Toxicol. 22(1): 1-21.
32.
Wrighton SA , Stevens JC, Becker GW, and VandenBranden M. (1993). Isolation and characterization of human liver cytochrome P450 2C19: Correlation between 2C19 and S-mephenytoin 4'-hydroxylation. Arch. Biochem. Biophysics306(1): 240-245.
33.
Wrighton SA , VandenBranden M., Stevens JC, Shipley LA, Ring BJ, Rettie AE, and Cashman JR (1993). In vitro methods for assessing human hepatic drug metabolism: Their use in drug development. Drug Metab. Rev. 25(4): 453-484.
34.
Zhou HH, Sheller JR, Nu H., Wood M., and Wood AJJ (1993). Ethnic differences in response to morphine. Clin. Pharmacol. Ther. 54(5): 507-513.
